Abstract: An information handling system may include a processor, a touchpad communicatively coupled to the processor, and non-transitory computer-readable media communicatively coupled to the processor and having stored thereon a program of instructions configured to, when read and executed by the processor in response to a trigger for enabling logical segmentation of the touchpad, logically segment the touchpad into a plurality of zones and map each zone to a respective corresponding feature displayed on one or more displays communicatively coupled to the processor such that user interaction with each of the plurality of zones manipulates the respective corresponding feature of such zones on the one or more displays.

Abstract: An information handling system may include a processor, a touchpad communicatively coupled to the processor, and non-transitory computer-readable media communicatively coupled to the processor and having stored thereon a program of instructions configured to, when read and executed by the processor in response to a trigger for enabling logical segmentation of the touchpad, logically segment the touchpad into a plurality of zones and map each zone to a respective corresponding feature displayed on one or more displays communicatively coupled to the processor such that user interaction with each of the plurality of zones manipulates the respective corresponding feature of such zones on the one or more displays.

Abstract: Compositions and methods are provided according to aspects of the present disclosure for inhibition of a pathogenic virus. According to particular aspects, compositions and methods of the present disclosure include degradation of pathogenic viral nucleic acids by interferon-stimulated gene 20-kDa protein (ISG20) and/or a variant thereof, administered to a cell and/or subject to inhibit a pathogenic viral infection of the cell and/or a subject. Compositions and methods are provided according to aspects of the present disclosure wherein providing the ISG20 protein, or a variant thereof, comprises administering a therapeutically effective amount of the ISG20 protein and/or variant, to a subject having, or at risk of having, a viral infection.